Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Informing Tobacco Regulatory Policy Through Laboratory Assessment of Appeal and Demand for Flavored Tobacco Products Among Young Adults
Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.
Transtubular microendoscopic approach for resection of a choroidal arteriovenous malformation.
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome? Curr Opin Cardiol. 2014 Jul; 29(4):301-6.
View in:
PubMed
subject areas
Acute Coronary Syndrome
Aspirin
Humans
Myocardial Ischemia
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Randomized Controlled Trials as Topic
Stents
Ticlopidine
Time Factors
authors with profiles
Usman Baber